7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.

Acid addition salt of pyrimethamine (5-4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine) and methane sulfonic acid, process for its preparation and pharmaceutical compositions comprising the acid addition salt are disclosed.

Acid addition salt of pyrimethamine (5-4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine) and methane sulfonic acid, process for its preparation and pharmaceutical compositions comprising the acid addition salt are disclosed.

A crystal form and a salt form of a uracil compound acting as a c-MET/AXL inhibitor and a preparation method therefor, specifically relating to the crystal form and the salt form of the compound shown in formula (I), and also comprising an application of the crystal form and the salt form in the preparation of drugs for the treatment of tumours.

##STR00001##

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W, X, Y, and Z are each as defined in the specification: ##STR00001##

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W, X, Y, and Z are each as defined in the specification: ##STR00001##

The present disclosure, in general, relates to portable/transportable apparatuses, methods, and systems for generating and delivering sulfur trioxide on-site or near an item to be treated. The present disclosure also relates to portable/transportable apparatuses, methods, and systems or extracting hydrocarbons from deposits containing a clathrate hydrate such as methane hydrates.

The present disclosure, in general, relates to portable/transportable apparatuses, methods, and systems for generating and delivering sulfur trioxide on-site or near an item to be treated. The present disclosure also relates to portable/transportable apparatuses, methods, and systems or extracting hydrocarbons from deposits containing a clathrate hydrate such as methane hydrates.

A quantum dot composition includes a quantum dot, and a ligand bonded to a surface of the quantum dot, wherein the ligand includes a head portion bonded to the surface of the quantum dot and containing a polar solvent dissociative functional group, and a tail portion connected to the head portion. A quantum dot composition according to an embodiment is used to form an emission layer of a light emitting element to enhance luminous efficiency of the light emitting element including an emission layer formed through the quantum dot composition.

A quantum dot composition includes a quantum dot, and a ligand bonded to a surface of the quantum dot, wherein the ligand includes a head portion bonded to the surface of the quantum dot and containing a polar solvent dissociative functional group, and a tail portion connected to the head portion. A quantum dot composition according to an embodiment is used to form an emission layer of a light emitting element to enhance luminous efficiency of the light emitting element including an emission layer formed through the quantum dot composition.